Fennec Pharmaceuticals Inc. (FENC) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Research Triangle Park, NC, アメリカ. 現CEOは Robert C. Andrade.
FENC を有する IPO日 2017-09-15, 32 名の正社員, に上場 NASDAQ Capital Marke, 時価総額 $178.63M.
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
